NCT01376245 - A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD | Biotech Hunter

Enrollment

646

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

fluticasone furoate/vilanterol

Inhaled corticosteroid/long acting beta-agonist

DRUG

Placebo

matching placebo

Trial Locations (34)

100

GSK Investigational Site, Taipei

112

GSK Investigational Site, Taipei

333

GSK Investigational Site, Tau-Yuan County

404

GSK Investigational Site, Taichung

500

GSK Investigational Site, Changhua

833

GSK Investigational Site, Kaohsiung City

1100

GSK Investigational Site, Quezon City

1109

GSK Investigational Site, Quezon City

40201

GSK Investigational Site, Taichung

40705

GSK Investigational Site, Taichung

100020

GSK Investigational Site, Beijing

100034

GSK Investigational Site, Beijing

100048

GSK Investigational Site, Beijing

100191

GSK Investigational Site, Beijing

110001

GSK Investigational Site, Shenyang

110015

GSK Investigational Site, Shenyang

200025

GSK Investigational Site, Shanghai

200080

GSK Investigational Site, Shanghai

200433

GSK Investigational Site, Shanghai

300052

GSK Investigational Site, Tianjin

310003

GSK Investigational Site, Hangzhou

400037

GSK Investigational Site, Chongqing

400038

GSK Investigational Site, Chongqing

410011

GSK Investigational Site, Changsha

410013

GSK Investigational Site, Changsha

510120

GSK Investigational Site, Guangzhou

510515

GSK Investigational Site, Guangzhou

530021

GSK Investigational Site, Nanning

610041

GSK Investigational Site, Chengdu

710032

GSK Investigational Site, Xi'an

710061

GSK Investigational Site, Xi'an

561-712

GSK Investigational Site, Jeonju-si, Jeollabuk-Do

158-710

GSK Investigational Site, Seoul

442-723

GSK Investigational Site, Suwon, Gyeonggi-do